TABLE OF CONTENTS
1 INTRODUCTION 60
1.1 OBJECTIVES OF THE STUDY 60
1.2 MARKET DEFINITION 60
1.3 OVERVIEW OF THE NORTH AMERICA LIQUID BIOPSY MARKET 60
1.4 LIMITATIONS 62
1.5 MARKETS COVERED 62
2 MARKET SEGMENTATION 66
2.1 MARKETS COVERED 66
2.2 GEOGRAPHICAL SCOPE 67
2.3 YEARS CONSIDERED FOR THE STUDY 68
2.4 CURRENCY AND PRICING 68
2.5 DBMR TRIPOD DATA VALIDATION MODEL 69
2.6 MULTIVARIATE MODELLING 72
2.7 PRODUCT TYPE LIFELINE CURVE 72
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 73
2.9 DBMR MARKET POSITION GRID 74
2.10 MARKET TESTING TYPE COVERAGE GRID 75
2.11 VENDOR SHARE ANALYSIS 76
2.12 SECONDARY SOURCES 77
2.13 ASSUMPTIONS 77
3 EXECUTIVE SUMMARY 78
4 PREMIUM INSIGHTS 81
4.1 PESTEL ANALYSIS 82
4.2 PORTERS FIVE FORCES 83
5 INDUSTRY INSIGHTS: 84
6 NORTH AMERICA LIQUID BIOPSY MARKET, REGULATION 85
7 MARKET OVERVIEW 87
7.1 DRIVERS 89
7.1.1 GROWING DEMAND FOR NON-INVASIVE LIQUID BIOPSY TECHNIQUE 89
7.1.2 ADVANCEMENTS IN PRECISION MEDICINE DUE TO LIQUID BIOPSY 90
7.1.3 INCREASING CANCER PREVALENCE AND AWARENESS 91
7.1.4 TECHNOLOGICAL ADVANCEMENTS IN LIQUID BIOPSY PLATFORMS 92
7.2 RESTRAINTS 93
7.2.1 HIGH COST OF LIQUID BIOPSY TESTS 93
7.2.2 LACK OF STANDARDIZED GUIDELINES 94
7.3 OPPORTUNITIES 95
7.3.1 INTEGRATION OF ARTIFICIAL INTELLIGENCE (AI) AND MACHINE LEARNING 95
7.3.2 INCREASING REIMBURSEMENTS AND GOVERNMENT SUPPORT FOR LIQUID BIOPSY 96
7.3.3 INCREASING R&D ACTIVITIES BY INSTITUTES 96
7.4 CHALLENGES 97
7.4.1 LACK OF SKILLED PROFESSIONALS PERFORMING LIQUID BIOPSY 97
7.4.2 INCREASED DEPENDENCY ON OTHER BIOPSIES 98
8 NORTH AMERICA LIQUID BIOPSY MARKET, BY PRODUCT 99
8.1 OVERVIEW 100
8.2 CONSUMABLES & ACCESSORIES 103
8.2.1 TEST KITS 104
8.2.1.1 TOTAL NUCLEIC ACID ISOLATION KIT 104
8.2.1.2 DNA ISOLATION KIT 104
8.2.1.3 OTHERS 104
8.2.2 COLLECTION TUBES 104
8.2.2.1 50 PIECES 105
8.2.2.2 100 PIECES 105
8.2.3 ASSAYS 105
8.2.3.1 FLEXIBLE REAGENTS 105
8.2.3.2 SCALABLE REAGENTS 105
8.2.3.3 OTHERS 105
8.2.4 CONTROL KIT 105
8.2.5 OTHERS 105
8.3 INSTRUMENTS 105
8.3.1 ANALYZERS 106
8.3.2 SYSTEMS 106
8.3.3 OTHERS 107
8.4 SERVICES & SOFTWARE 107
8.4.1 NGS ANALYSIS AND REPORTING SOFTWARE 108
8.4.2 DPCR ANALYSIS SOFTWARE 108
8.4.3 CASTPCR ANALYSIS SOFTWARE 108
8.4.4 OTHERS 108
9 NORTH AMERICA LIQUID BIOPSY MARKET, BY BIOMAKER TYPE 109
9.1 OVERVIEW 110
9.2 CIRCULATING TUMOR CELLS (CTCS) 113
9.3 CIRCULATING CELL-FREE DNA (CFDNA) 114
9.4 CELL-FREE RNA 115
9.5 EXOSOMES 116
9.6 EXTRACELLULAR VESICLES 117
9.7 OTHERS 118
10 NORTH AMERICA LIQUID BIOPSY MARKET, BY SAMPLE TYPE 119
10.1 OVERVIEW 120
10.2 BLOOD SAMPLE-BASED 123
10.3 URINE SAMPLE-BASED 124
10.4 SALIVA & OTHER TISSUE FLUIDS SAMPLE-BASED 125
10.5 OTHERS 126
11 NORTH AMERICA LIQUID BIOPSY MARKET, BY ANALYTICAL TYPE 127
11.1 OVERVIEW 128
11.2 MOLECULAR 131
11.2.1 NGS 132
11.2.2 PCR 132
11.2.3 MICROARRAY 132
11.2.4 PROTEOMICS 132
11.2.5 OTHERS 132
11.3 PROTEOMIC 132
11.3.1 NGS 133
11.3.2 PCR 133
11.3.3 MICROARRAY 133
11.3.4 PROTEOMICS 133
11.3.5 OTHERS 133
11.4 HISTOLOGY/IMAGING 134
12 NORTH AMERICA LIQUID BIOPSY MARKET, BY APPLICATION TYPE 135
12.1 OVERVIEW 136
12.2 CANCER APPLICATIONS 139
12.2.1 LUNG 140
12.2.2 BREAST 140
12.2.2.1 EARLY BREAST CANCER 140
12.2.2.2 ADVANCED BREAST CANCER 140
12.2.3 COLORECTAL 140
12.2.4 PROSTRATE 141
12.2.5 LIVER 141
12.2.6 OTHERS 141
12.3 NON-CANCER APPLICATIONS 141
12.3.1 PRENATAL DIAGNOSIS 142
12.3.2 PERSONALIZED IMMUNOTHERAPY 142
12.3.3 OTHERS 142
13 NORTH AMERICA LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION 143
13.1 OVERVIEW 144
13.2 ROUTINE SCREENING 147
13.3 THERAPY SELECTION 148
13.4 TREATMENT MONITORING 148
13.4.1 EARLY-STAGE DISEASE 149
13.4.2 LATE-STAGE/METASTATIC DISEASE 149
13.5 RECURRENCE MONITORING 150
13.6 PATIENT WORK-UP 150
13.7 OTHERS 151
14 NORTH AMERICA LIQUID BIOPSY MARKET, BY TECHNOLOGY 152
14.1 OVERVIEW 153
14.2 MULTI-GENE-PARALLEL ANALYSIS 156
14.3 SINGLE GENE ANALYSIS 157
15 NORTH AMERICA LIQUID BIOPSY MARKET, BY END USER 158
15.1 OVERVIEW 159
15.2 HOSPITALS 162
15.3 REFERENCE LABORATORIES 162
15.4 DIAGNOSTIC CENTERS 163
15.5 RESEARCH CENTERS AND ACADEMIC INSTITUTES 163
15.6 OTHERS 165
16 NORTH AMERICA LIQUID BIOPSY MARKET, BY DISTRIBUTION CHANNEL 166
16.1 OVERVIEW 167
16.2 DIRECT TENDER 170
16.3 THIRD PARTY DISTRIBUTOR 170
16.4 OTHERS 171
17 NORTH AMERICA LIQUID BIOPSY MARKET, BY REGION 172
17.1 NORTH AMERICA 173
17.1.1 U.S. 187
17.1.2 CANADA 196
17.1.3 MEXICO 205
18 NORTH AMERICA LIQUID BIOPSY MARKET, COMPANY LANDSCAPE 214
18.1 COMPANY SHARE ANALYSIS: NORTH AMERICA 214
19 COMPANY PROFILE 215
19.1 F. HOFFMANN-LA ROCHE LTD. 215
19.1.1 COMPANY SNAPSHOT 215
19.1.2 REVENUE ANALYSIS 215
19.1.3 COMPANY SHARE ANALYSIS 216
19.1.4 PRODUCT PORTFOLIO 216
19.1.5 RECENT DEVELOPMENTS 216
19.2 GUARDANT HEALTH 217
19.2.1 COMPANY SNAPSHOT 217
19.2.2 REVENUE ANALYSIS 217
19.2.3 COMPANY SHARE ANALYSIS 218
19.2.4 PRODUCT PORTFOLIO 218
19.2.5 RECENT DEVELOPMENTS 218
19.3 THERMO FISHER SCIENTIFIC INC. 219
19.3.1 COMPANY SNAPSHOT 219
19.3.2 REVENUE ANALYSIS 219
19.3.3 COMPANY SHARE ANALYSIS 220
19.3.4 SWOT ANALYSIS 220
19.3.5 PRODUCT PORTFOLIO 221
19.3.6 RECENT DEVELOPMENTS 222
19.4 EXACT SCIENCE CORPORATION 223
19.4.1 COMPANY SNAPSHOT 223
19.4.2 REVENUE ANALYSIS 223
19.4.3 COMPANY SHARE ANALYSIS 224
19.4.4 PRODUCT PORTFOLIO 224
19.4.5 RECENT DEVELOPMENTS 224
19.5 QIAGEN 225
19.5.1 COMPANY SNAPSHOT 225
19.5.2 REVENUE ANALYSIS 225
19.5.3 COMPANY SHARE ANALYSIS 226
19.5.4 PRODUCT PORTFOLIO 226
19.5.5 RECENT DEVELOPMENTS 227
19.6 ANGLE PLC (2022) 228
19.6.1 COMPANY SNAPSHOT 228
19.6.2 REVENUE ANALYSIS 228
19.6.3 PRODUCT PORTFOLIO 229
19.6.4 RECENT DEVELOPMENT 229
19.7 BIOCEPT, INC. 230
19.7.1 COMPANY SNAPSHOT 230
19.7.2 REVENUE ANALYSIS 230
19.7.3 PRODUCT PORTFOLIO 231
19.7.4 RECENT DEVELOPMENT 231
19.8 BIO-RAD LABORATORIES, INC. (2022) 232
19.8.1 COMPANY SNAPSHOT 232
19.8.2 REVENUE ANALYSIS 232
19.8.3 PRODUCT PORTFOLIO 233
19.8.4 RECENT DEVELOPMENTS 233
19.9 EPIC SCIENCES 234
19.9.1 COMPANY SNAPSHOT 234
19.9.2 PRODUCT PORTFOLIO 234
19.9.3 RECENT DEVELOPMENTS 234
19.10 FLUXION BIOSCIENCES INC 235
19.10.1 COMPANY SNAPSHOT 235
19.10.2 PRODUCT PORTFOLIO 235
19.10.3 RECENT DEVELOPMENTS 235
19.11 ILLUMINA, INC. 236
19.11.1 COMPANY SNAPSHOT 236
19.11.2 REVENUE ANALYSIS 236
19.11.3 SWOT ANALYSIS 237
19.11.4 PRODUCT PORTFOLIO 237
19.11.5 RECENT DEVELOPMENT 237
19.12 JOHNSON & JOHNSON PRIVATE LIMITED 239
19.12.1 COMPANY SNAPSHOT 239
19.12.2 REVENUE ANALYSIS 239
19.12.3 SWOT ANALYSIS 240
19.12.4 PRODUCT PORTFOLIO 240
19.12.5 RECENT DEVELOPMENTS 240
19.13 LABORATORY CORPORATION OF AMERICA HOLDINGS 241
19.13.1 COMPANY SNAPSHOT 241
19.13.2 REVENUE ANALYSIS 241
19.13.3 SWOT ANALYSIS 242
19.13.4 PRODUCT PORTFOLIO 242
19.13.5 RECENT DEVELOPMENT 242
19.14 MDXHEALTH 243
19.14.1 COMPANY SNAPSHOT 243
19.14.2 REVENUE ANALYSIS 243
19.14.3 PRODUCT PORTFOLIO 244
19.14.4 RECENT DEVELOPMENTS 244
19.15 MENARINI SILICON BIOSYSTEMS 245
19.15.1 COMPANY SNAPSHOT 245
19.15.2 PRODUCT PORTFOLIO 245
19.15.3 RECENT DEVELOPMENTS 245
19.16 NATERA, INC. 246
19.16.1 COMPANY SNAPSHOT 246
19.16.2 REVENUE ANALYSIS 246
19.16.3 PRODUCT PORTFOLIO 247
19.16.4 RECENT DEVELOPMENTS 247
19.17 NEOGENOMICS LABORATORIES 248
19.17.1 COMPANY SNAPSHOT 248
19.17.2 REVENUE ANALYSIS 248
19.17.3 PRODUCT PORTFOLIO 249
19.17.4 RECENT DEVELOPMENTS 249
19.18 ONCOCYTE CORPORATION 250
19.18.1 COMPANY PROFILE 250
19.18.2 SERVICE PORTFOLIO 250
19.18.3 RECENT DEVELOPMENTS 250
19.19 PATHAI 251
19.19.1 COMPANY SNAPSHOT 251
19.19.2 PRODUCT PORTFOLIO 251
19.19.3 RECENT DEVELOPMENTS 251

Menu 2

Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam.